Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 5
2006 2
2007 5
2008 1
2009 5
2010 5
2011 4
2012 7
2013 4
2014 2
2015 2
2017 3
2018 3
2019 7
2020 3
2021 7
2022 8
2023 9
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

77 results

Results by year

Filters applied: . Clear all
Page 1
TLR4 enhances TGF-beta signaling and hepatic fibrosis.
Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. Seki E, et al. Among authors: osawa y. Nat Med. 2007 Nov;13(11):1324-32. doi: 10.1038/nm1663. Epub 2007 Oct 21. Nat Med. 2007. PMID: 17952090
Sphingosine-1-phosphate promotes tumor development and liver fibrosis in mouse model of congestive hepatopathy.
Kawai H, Osawa Y, Matsuda M, Tsunoda T, Yanagida K, Hishikawa D, Okawara M, Sakamoto Y, Shimagaki T, Tsutsui Y, Yoshida Y, Yoshikawa S, Hashi K, Doi H, Mori T, Yamazoe T, Yoshio S, Sugiyama M, Okuzaki D, Komatsu H, Inui A, Tamura-Nakano M, Oyama C, Shindou H, Kusano H, Kage M, Ikegami T, Yanaga K, Kanto T. Kawai H, et al. Among authors: osawa y. Hepatology. 2022 Jul;76(1):112-125. doi: 10.1002/hep.32256. Epub 2021 Dec 22. Hepatology. 2022. PMID: 34855990
Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M, Nishikawa K, Osawa Y, Imamura J, Yamaji K, Harada K, Yatsuhashi H, Murata K, Miura K, Tanaka A, Kanto T, Kohara M, Kamisawa T, Kimura K. Kimura M, et al. Among authors: osawa y. Hepatol Commun. 2022 Oct;6(10):2732-2747. doi: 10.1002/hep4.2043. Epub 2022 Jul 20. Hepatol Commun. 2022. PMID: 35855613 Free PMC article.
Liver disease secondary to congenital heart disease in children.
Komatsu H, Inui A, Kishiki K, Kawai H, Yoshio S, Osawa Y, Kanto T, Fujisawa T. Komatsu H, et al. Among authors: osawa y. Expert Rev Gastroenterol Hepatol. 2019 Jul;13(7):651-666. doi: 10.1080/17474124.2019.1621746. Epub 2019 May 26. Expert Rev Gastroenterol Hepatol. 2019. PMID: 31131680 Review.
Molecular insights of a CBP/β-catenin-signaling inhibitor on nonalcoholic steatohepatitis-induced liver fibrosis and disorder.
Yamaji K, Iwabuchi S, Tokunaga Y, Hashimoto S, Yamane D, Toyama S, Kono R, Kitab B, Tsukiyama-Kohara K, Osawa Y, Hayashi Y, Hishima T, Tateno C, Kimura K, Okanoue T, Kohara M. Yamaji K, et al. Among authors: osawa y. Biomed Pharmacother. 2023 Oct;166:115379. doi: 10.1016/j.biopha.2023.115379. Epub 2023 Aug 28. Biomed Pharmacother. 2023. PMID: 37647690 Free article.
Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model.
Tsutsui Y, Mori T, Yoshio S, Sato M, Sakata T, Yoshida Y, Kawai H, Yoshikawa S, Yamazoe T, Matsuda M, Kakazu E, Osawa Y, Oyama C, Tamura-Nakano M, Kawaguchi T, Yoshizumi T, Kanto T. Tsutsui Y, et al. Among authors: osawa y. Hepatol Commun. 2023 Sep 27;7(10):e0236. doi: 10.1097/HC9.0000000000000236. eCollection 2023 Oct 1. Hepatol Commun. 2023. PMID: 37756046 Free PMC article.
77 results